Powered by HealthTechMovers.com
We added 3 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Seagen, SGEN
Summary: Seagen, Inc., a biotechnology company, focuses on developing & commercializing therapies targeted for the treatment of cancer. Adcetris, a lead FDA approved marketed product at Seagen, is used for treating Hodgkin lymphoma, certain T-cell lymphomas, other cancers in the U.S., Europe & several countries. Seagen has an agreement with Takeda Pharmaceutical Company Ltd. for the further development and commercialization of Adcetris. Seagen retains all rights to sell Adcetris in the U.S. and Canada, while Takeda has commercial rights to the drug in the rest of the world. The FDA granted approvals to Seagen's several drugs named Padcev, for treating advanced/metastatic urothelial cancer; Tukysa and Tivdak for treating adult patients with locally advanced/metastatic HER2-positive breast cancer and for the treatment of recurrent/metastatic cervical cancer in adult patients respectively. The company also has license agreements with partners like Merck, Roche, GlaxoSmithKline, Astellas, AbbVie, Bristol-Myers and Genmab.
- Last Price: $199.50
- Price Change: -$0.49, -0.25%
- Yearly Gain: 67.42%
- Market Cap: $37.50B
- P/E Ratio: -57.205
Here are 3rd party ratings for SGEN:
- TipRanks.com: Moderate Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 39% (98 out of 251)
What is the sentiment on the street regarding Seagen ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Very Low
- Insider Signal: Positive
- Investor Sentiment: Positive
- Hedge Fund signal: Very Positive
If you are interested in SGEN or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on SGEN before you decide to make any investment.
Click here for chart >>
Morphic Holding, MORF
Summary: Morphic Holding Inc. is a biopharmaceutical company. It focuses on the discovery and development of oral small-molecule integrin therapeutics for autoimmune, cardiovascular and metabolic diseases, as well as fibrosis and cancer. Morphic Holding Inc. is based in Waltham, Massachusetts.
- Last Price: $57.50
- Price Change: -$0.19, -0.33%
- Yearly Gain: 158.58%
- Market Cap: $2.60B
- P/E Ratio: -35.305
Here are 3rd party ratings for MORF:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 39% (98 out of 251)
What is the sentiment on the street regarding Morphic Holding ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Low
- Insider Signal: Very Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Very Positive
If you are interested in MORF or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on MORF before you decide to make any investment.
Click here for chart >>
89bio, ETNB
Summary: 89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is being developed for the treatment of nonalcoholic steatohepatitis. 89bio Inc. is headquartered in San Francisco.
- Last Price: $17.59
- Price Change: -$0.53, -2.92%
- Yearly Gain: 742.79%
- Market Cap: $1.32B
- P/E Ratio: -6.414
Here are 3rd party ratings for ETNB:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 39% (98 out of 251)
What is the sentiment on the street regarding 89bio ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Positive
If you are interested in ETNB or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on ETNB before you decide to make any investment.
Click here for chart >>
Thanks for reading!